Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

Table 3 Characteristics of patients with BM-CR

Pt	Pts	DG	DX_ time to enroll., mos	HR DUR, mos	Mol. status	DUR of therapy, mos	Initial BM^b	Best BM resp.—time from enroll., mos	Last BM	Resp. DUR, mos
1^a	59 M	PV	97	79.7*	PMR	15.3	MF 2, 90%, OST	MF 0, NEG morph. and OST, 40%—43	MF 1, NEG morph., 60%	30
2^a	75 F	PV	119	89.4	CMR	91.4	MF 2, 80%	MF 0, NEG morph., 50%—48	MF 1, NEG morph., 50%	48
3^a	38 M	PV	1	100.9	CMR	100.9	MF 2, 90%, OST	MF 1, NEG morph. and OST, 30%—56	MF 1, NEG morph and OST., 50%	40
4	58 M	PV	35	87.1*	CMR	99.0	MF 2, 90%, OST	MF 0, NEG morph. and OST, 30%—69	MF 1, POS morph., 60%	48
5	37 F	PV	5	94.8	CMR	94.8	MF 1, 70%, OST	MF 0, NEG morph., 40%—60	MF 1, NEG morph., 40%, + OST	48
6^a	44 M	PV	3	74.7*	CMR	98.3	MF 1, 70%	MF 0, NEG morph., 30%—48	MF 1, NEG morph., 50%	36
7	46 M	PV	350	79.5	PMR	79.5	MF 1, 60%	MF 0, NEG morph., 40%—48	MF 1, POS morph., 50%	30
8^a	47 F	ET	33	83.0	CMR	83.0	MF 1, 50%	MF 1, NEG morph., 20%—60	MF 0, NEG morph., 30%	24
9^a	35 M	ET	14	79.8	CMR	30.4	MF 1, 50%	MF 0, NEG morph., 30%—30	MF 0, NEG morph., 50%	52
10^a	53 F	ET	43	91.7	NR	58.7	MF 1, 50%	MF 0, NEG morph., 40%—48	MF 0, NEG morph., 20%	24
11^a	39 F	ET	2	92.6	TN	18.1	MF 1, 50%	MF 0, NEG morph., 40%—66	MF 0, NEG morph., 40%	24
12^a	23 F	ET	30	100.8	TN	91.5	MF 1, 20%	MF 1, NEG morph., 30%—60	MF 0, NEG morph., 30%	24
13	73 F	ET	110	59.3*	PMR	30.4	MF 2, 60%, OST	MF 1, NEG morph., 30%—30	MF 1, POS morph., 40%	24

DUR duration, DX diagnosis, OST osteosclerosis, Resp response, morph. morphology, enroll. enrollment to study, NEG negative, POS positive
^aPatients who sustained a BM response at last follow-up, * lost HR
^bBM description includes degree of reticulin fibrosis on scale of 0–3, % BM cellularity, and presence of osteosclerosis (OST)

ISSN: 2162-3619